Abstract
In a series of pts with muscle invading BC treated with a conservative approach a multivariate regression analysis was carried on to evaluate the association of clinical and pathological factors with clinical response and survival. Seventy pts with T1G3-T4 N0 M0 BC were treated with transurethral resection (TUR) and an alternating chemo-radiotherapy (CT-RT). Characteristics of pts were: median age, 65 yrs (range 40–75 yrs); median ECOG PS, 0 (range 0–1); M/F, 64/6; T1G3, 7 pts; T2, 40 pts; T3, 19 pts; T4, 4 pts; G2, 24 pts; G3, 42 pts. The first 18 pts received 4 cycles of CDDP 20 mg/sqm and FU 200 mg/sqm dd. 1–5 during wks 1, 4, 7, 10 alternated with RT (40 Gy during wks 2, 3, 8, 9). The second group of 52 pts received 3 cycles of the same CT (wks 1, 4, 7) (except the last 20 pts who received MTX 40 mg/sqm dd. 1, 8 instead of FU) alternated with 50 Gy of RT (wks 2, 3, 5, 6). Correlation of clinical and pathological features with response and survival: Response (P) Survival (P) Tumor stage T1–T2/T3–T4 0.7 0.7 Grade G1–G2/G3 0.5 0.9 TUR complete/incomplete 0.0004 0.009 Preop. hemogl. ≤12/>21 0.5 0.8 Hydronephrosis yes/no 0.6 0.7 In our group of pts the macroscopic radicality of TUR was the only significant prognostic factor. In fact pts with residual macroscopic disease after TUR had a 3.9 higher RR of death than pts with no residual disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
